<DOC>
	<DOCNO>NCT02466152</DOCNO>
	<brief_summary>This study assess systemic exposure pharmacokinetic parameter GSK2894512 follow twice daily topical administration 1 % 2 % cream adult subject AD , provide information systemic safety well local safety tolerability follow twice daily application 35 % body surface area ( BSA ) affect skin subject AD . It open-label , sequential study consist 2 cohort . A cohort 6 subject ( Cohort 1 ) apply GSK2894512 ( cream , 2 % ) affect skin area range 15 35 % total BSA 20 day plus final dose Day 21 . Cohort 2 consist 6 subject apply 1 % cream . Cohort 2 follow procedure Cohort 1 .</brief_summary>
	<brief_title>Pharmacokinetic Study Topical GSK2894512 Cream</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<criteria>Between 18 65 year age inclusive , time signing informed consent Confirmed clinical diagnosis AD accord establish criterion Hanifin screen visit . History AD least 6 month . Atopic dermatitis 1535 % , BSA , ( scalp area around eye include treatment area ) baseline . Note : 1 % BSA approximately equal surface one hand finger together ( handprint ) An IGA AD score &gt; =3 baseline . Male : Male subject female partner child bear potential must comply follow contraception requirement time first dose study medication least five halflives study medication last dose study medication : 1 . Vasectomy documentation azoospermia . 2 . Male condom plus partner use one contraceptive option : Contraceptive subdermal implant meet standard operate procedure ( SOP ) effectiveness criterion include &lt; 1 % rate failure per year , state product label ; Intrauterine device intrauterine system meet SOP effectiveness criterion include &lt; 1 % rate failure per year , state product label ; Oral Contraceptive , either combined progestogen alone , Injectable progestogen ; Contraceptive vaginal ring ; Percutaneous contraceptive patch . These allow method contraception effective use consistently , correctly accordance product label . The investigator responsible ensure subject understand properly use method contraception . A woman eligible participate nonreproductive potential , define : 1 . Postmenopausal ( include woman 60 year age ) . 2 . Females one follow procedure document plan utilize assist reproductive technique ( e.g. , vitro fertilization donor embryo transfer ) : Bilateral tubal ligation salpingectomy ; Hysteroscopic tubal occlusion procedure followup confirmation bilateral tubal occlusion ; Hysterectomy ; Bilateral oophorectomy ( surgical menopause ) Note : A practical definition accepts menopause 1 year without menses appropriate clinical profile ( e.g. , age appropriate , &gt; 45 year , absence hormone replacement therapy [ HRT ] medical suppression menstrual cycle ) . In questionable case woman &lt; 60 year age , blood sample simultaneous follicle stimulate hormone estradiol fall central laboratory 's postmenopausal reference range confirmatory . Women &lt; 60 year age HRT , wish continue , whose menopausal status doubt require use highlyeffective method avoid pregnancy . Otherwise , must discontinue HRT allow confirmation postmenopausal status study enrollment . For form HRT , least 2 4 week elapse cessation therapy blood draw ; interval depend type dosage HRT . Following confirmation postmenopausal status , HRT may resume study without use highlyeffective method avoid pregnancy Capable give sign informed consent describe Protocol include compliance requirement restriction list consent form protocol . Alanine aminotransferase ( ALT ) bilirubin &gt; 1.5x Upper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) screening . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) QTc &gt; 450 millisecond ( msec ) QTc &gt; 480 msec subject Bundle Branch Block . NOTES : The QTc QT interval correct heart rate accord Bazett 's formula ( QTcB ) , Fridericia 's formula ( QTcF ) , and/or another method , machineread manually overread . The specific formula use determine eligibility discontinuation individual subject determine prior initiation study . In word , several different formula use calculate QTc individual subject low QTc value use include discontinue subject trial . For purpose data analysis , QTcB , QTcF , another QT correction formula , composite available value QTc use specify Reporting Analysis Plan ( RAP ) . Unstable course AD ( spontaneously improve rapidly deteriorate ) determine investigator previous 4 week prior dose ( Day 1 ) . Chronic acute infection require treatment systemic treatment ( antibiotic , antiviral , antiparasitics , antiprotozoal , antifungal ) within 4 week dose , superficial skin infection within 1 week screen visit . Concurrent condition history disease : Immunocompromized ( e.g. , lymphoma , Acquired Immuno Deficiency Syndrome , WiskottAldrich Syndrome ) history malignant disease within 5 year baseline visit ; Presence screen baseline active acute bacterial , fungal viral skin infection ( e.g. , herpes simplex , herpes zoster , chicken pox ) ; Any concomitant skin disorder ( e.g. , generalized erythroderma Netherton 's Syndrome , psoriasis ) , significant hyperpigmentation , extensive scar opinion investigator may interfere evaluation AD lesion compromise subject safety ; Clinical sign infection ( viral , fungal bacterial ) treatment area ; Other type eczema . Used prohibited medication list Protocol within indicate washout period Prolonged exposure natural artificial source ultraviolet ( UV ) radiation result sunburn within 2 week prior first dose And/or intention UV exposure study , think investigator likely modify subject 's AD . Planning use sauna duration study intend swim History sensitivity study medication , component thereof history drug allergy , opinion investigator Medical Monitor , contraindicate participation Presence hepatitis B surface antigen ( HBsAg ) , positive hepatitis C antibody test result screen within 3 month prior first dose study treatment . A positive drug/alcohol screen screen . A positive test Human immunodeficiency virus ( HIV ) antibody screen . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure 4 investigational medicinal product within 12 month prior first dose day . A history ongoing serious illness medical , physical , psychiatric condition ( ) , investigator 's opinion , may interfere subject 's completion study . Use anticoagulant medication ( e.g . heparin , Low Molecular Weight heparin , warfarin , antiplatelets [ Nonsteroidal antiinflammatory drug low dose aspirin 81 milligram consider anti platelet ] ) contraindication skin biopsy , history hypertrophic scar keloid formation scar suture sit , history allergic reaction significant sensitivity lidocaine local anesthetic . Use nicotinecontaining product ( include nicotine patch ) . Women pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>PK</keyword>
	<keyword>GSK2894512</keyword>
	<keyword>Atopic Dermatitis</keyword>
</DOC>